Breaking News
Get 50% Off 0
🧩 Based on my current watchlist, how should I diversify my portfolio?
Ask WarrenAI
Close

Alnylam Pharmaceuticals Inc DRC (A1LN34)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
117.24 +1.68    +1.45%
07/08 - Closed. Currency in BRL
Type:  Equity
Market:  Brazil
ISIN:  BRA1LNBDR003 
  • Volume: 12
  • Bid/Ask: 100.09 / 117.60
  • Day's Range: 117.24 - 118.81
Alnylam Pharmaceuticals DRC 117.24 +1.68 +1.45%

Alnylam Pharmaceuticals Inc DRC Company Profile

 
Get an in-depth profile of Alnylam Pharmaceuticals Inc DRC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

2230

Equity Type

DRC

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer’s disease; and ALN-HTT02 that is in phase I clinical trial for Huntington’s disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Contact Information

Address 675 West Kendall Street Henri A. Termeer Square
Cambridge, 02142
United States
Phone 617 551 8200
Fax 617 551 8101

Top Executives

Name Age Since Title
Yvonne L. Greenstreet 60 2016 CEO & Director
Amy W. Schulman 64 2014 Independent Chair of the Board
Muthiah Manoharan 72 2003 Senior VP of Innovation Chemistry & Distinguished Scientist and Member of Scientific Advisory Board
Phillip A. Sharp 80 2002 Co-Founder, Member of the Scientific Advisory Board
Markus Stoffel - - Member of Scientific Advisory Board
David P. Bartel - - Member of Scientific Advisory Board
Paul R. Schimmel 84 2002 Member of the Scientific Advisory Board
Rachel Meyers 61 - Member of Scientific Advisory Board
Colleen Foley Reitan 65 2018 Independent Director
Daniel J. Rader - - Member of Scientific Advisory Board
David E. I. Pyott 72 2015 Independent Director
Margaret A. Hamburg 70 2019 Independent Director
Michael Weston Bonney 67 2014 Non-Independent Director
Priya S. Kishnani - 2020 Member of the Scientific Advisory Board
Charles Elliott Sigal 73 2022 Independent Director
Dennis Arthur Ausiello 80 2012 Member of the Scientific Advisory Board & Independent Director
Nancy J. Brown - 2015 Member of Scientific Advisory Board
Olivier Brandicourt 69 2020 Independent Director
Carolyn R. Bertozzi 58 2023 Member of Scientific Advisory Board & Independent Director
Peter N. Kellogg 69 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

A1LN34 Comments

Write your thoughts about Alnylam Pharmaceuticals Inc DRC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email